Pipeline
The Science
About us
Investors

Hit enter to search or ESC to close

Presentation to Extraordinary General Meeting

December 29, 2023December 29, 2023 Alterity Therapeutics

EGM Presentation 2023

Post navigation

Alterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical Progress

Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones

Related Posts

Alterity Therapeutics Receives a $4.74 million Research & Development Tax Incentive Refund

August 15, 2023August 15, 2023

Alterity Therapeutics Completes Enrolment in ATH434-201 Phase 2 Clinical Trial in Multiple System Atrophy

November 8, 2023November 8, 2023

Alterity Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

January 5, 2022August 16, 2022

Recent Posts

Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson’s Disease and Movement Disorders®
XBRL 30 June 2024 filed with the SEC
Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer
Alterity Therapeutics to Deliver Multiple Oral and Poster Presentations at the International Congress of Parkinson’s Disease and Movement Disorders®
Appendix 4C – Q4 FY24 Quarterly Cash Flow Report

Recent Comments

Archives

Archives

Categories

ASX Announcements
Chairman's Address
Investor Announcement

Tags

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

LinkedIn
Facebook
X

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065